The most pressing practical application of JUQ-470 is the resolution of —the moment when a conversational agent’s context window fills, and it "wakes up" as a blank slate.
First-in-human (FIH) clinical plan
JUQ‑470’s approach aims to fill a niche where tumors rely on both FGFR‑driven proliferation and VEGF‑driven angiogenesis. JUQ-470
| Feature | JUQ‑470 | Representative Approved Agents | |---------|---------|--------------------------------| | | Yes (single molecule) | Typically separate agents (e.g., erdafitinib – FGFR; bevacizumab – VEGF) or multi‑kinase agents with broader off‑target profiles (e.g., lenvatinib). | | Selectivity | Nanomolar potency for FGFR1/VEGFR2, limited activity against >50 unrelated kinases (<100 nM) | Many multi‑kinase inhibitors hit >10 kinases at low nanomolar levels, leading to higher off‑target toxicity. | | Oral bioavailability | High (F > 70 % in rats) | Some VEGF inhibitors are IV (e.g., bevacizumab). | | Pharmacokinetic profile | Moderate half‑life (10‑14 h) → once‑daily dosing | Lenvatinib (half‑life ~28 h) → daily but with more dose‑adjustments for toxicity. | | Safety | Early data suggest manageable hypertension, mild GI side‑effects; no severe hepatotoxicity reported yet | Hypertension, proteinuria, and hand‑foot syndrome are common with existing TKIs. | The most pressing practical application of JUQ-470 is